You are here

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Avail Clinical Research, LLC
Deland, Florida, 32720 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Noncancer Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject has moderate to severe chronic noncancer pain (duration of at least 3 months)
requiring a continuous around-the-clock opioid analgesic for an extended period of
time. Conditions may include, but are not limited to, osteoarthritis, chronic low back
pain, or other opioid -responsive pain conditions.

- Subject agrees to refrain from taking opioid medications other than study drug during
the study. (The exception is during the Pre-Treatment Period when the subject may
continue current opioid therapy to guide first 4 weeks of the Treatment Period when
the subject may administer immediate-release oxycodone to support conversion to study
drug.)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subject has moderate or severe chronic pain due to cancer, migraine, recent trauma,
infection, or other pain expected to be short-term (duration less than 3 months).

- Subject has a documented history of alcohol or drug abuse within 1 year prior to study
entry that in the Investigator's judgment would impact subject participation.

- Subject has ongoing or active alcohol or drug abuse that in the Investigator's
judgment would impact subject participation.

- Subject has a positive urine drug test for illicit drug use or medications at
screening without legitimate medical explanation.

- Subject has a clinically significant medical condition (e.g., cardiovascular,
neurological, renal, hepatic, pulmonary, gastrointestinal, endocrine, hematological,
immunological, rheumatological, metabolic, or psychiatric) or physical examination,
vital signs (VS), 12-lead electrocardiogram (ECG), clinical laboratory abnormalities
that in the opinion of the Investigator would impact the safety of the subject during
study participation.

- If female, the subject is pregnant or breast-feeding.

- Subject has a known history or known hypersensitivity to oxycodone, oxycodone salts,
naltrexone or acetaminophen,or pharmacological similar compounds.

- Subject is historically non-responsive to oxycodone treatment or requires greater than
160 mg oxycodone in a 24-hour time interval.

NCT01428583
Pfizer
Completed
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now